Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company National OncoVenture
DescriptionFirst in class modulator of DLK1
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today